Who are Arm B: Daratumumab Hyaluronidase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Darzalex Faspro, Darzalex, SCT800 and Daratumumab, Daratumumab and corticosteroid treatment, Darzalex, SARCLISA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arm-b-daratumumab-hyaluronidase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Arm B: Daratumumab Hyaluronidase — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Arm B: Daratumumab Hyaluronidase (Arm B: Daratumumab Hyaluronidase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD38-targeting monoclonal antibody. Area: Oncology.

phase 3 CD38-targeting monoclonal antibody CD38 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Arm B: Daratumumab Hyaluronidase (Arm B: Daratumumab Hyaluronidase) — PrECOG, LLC.. Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while hyaluronidase enables subcutaneous administration by breaking down hyaluronic acid in subcutaneous tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arm B: Daratumumab Hyaluronidase TARGET	Arm B: Daratumumab Hyaluronidase	PrECOG, LLC.	phase 3	CD38-targeting monoclonal antibody	CD38
Darzalex Faspro	daratumumab-and-hyaluronidase-fihj	Pfizer	marketed	CD38-directed Cytolytic Antibody [EPC]	CD38	2020-01-01
Darzalex	daratumumab	Johnson & Johnson	marketed	Monoclonal antibody	CD38	2015-01-01
SCT800 and Daratumumab	SCT800 and Daratumumab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab)	CD19 and CD3 (SCT800); CD38 (Daratumumab)
Daratumumab and corticosteroid treatment	Daratumumab and corticosteroid treatment	Institute of Hematology & Blood Diseases Hospital, China	marketed	Monoclonal antibody (CD38-targeting) combined with corticosteroid	CD38
Darzalex	Darzalex	Shanghai Henlius Biotech	marketed		Lymphocyte differentiation antigen CD38
SARCLISA	ISATUXIMAB-IRFC	SANOFI AVENTIS US	marketed	CD38-directed Cytolytic Antibody [EPC]	Lymphocyte differentiation antigen CD38

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD38-targeting monoclonal antibody class)

Janssen Research & Development, LLC · 4 drugs in this class
Charite University, Berlin, Germany · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Celltrion · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class
PrECOG, LLC. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arm B: Daratumumab Hyaluronidase — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-b-daratumumab-hyaluronidase. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab